371 related articles for article (PubMed ID: 36384423)
1. Identification of the cuproptosis-related molecular subtypes and an immunotherapy prognostic model in hepatocellular carcinoma.
Zhang L; Xu J; Chu X; Zhang H; Yao X; Zhang J; Guo Y
BMC Bioinformatics; 2022 Nov; 23(1):485. PubMed ID: 36384423
[TBL] [Abstract][Full Text] [Related]
2. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
[TBL] [Abstract][Full Text] [Related]
3. Prognostic and Immunological Significance of the Molecular Subtypes and Risk Signatures Based on Cuproptosis in Hepatocellular Carcinoma.
Tang X; Ren X; Huang T; Miao Y; Ha W; Li Z; Yang L; Mi D
Mediators Inflamm; 2023; 2023():3951940. PubMed ID: 37124062
[TBL] [Abstract][Full Text] [Related]
4. Relationships of Cuproptosis-Related Genes With Clinical Outcomes and the Tumour Immune Microenvironment in Hepatocellular Carcinoma.
Chen X; Hu G; Xiong L; Xu Q
Pathol Oncol Res; 2022; 28():1610558. PubMed ID: 36213162
[No Abstract] [Full Text] [Related]
5. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
Front Immunol; 2022; 13():990790. PubMed ID: 36248822
[TBL] [Abstract][Full Text] [Related]
6. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
7. Cuproptosis-related signature for clinical prognosis and immunotherapy sensitivity in hepatocellular carcinoma.
Xu S; Dong K; Gao R; Yang Y; Zhou Y; Luo C; Chen W; Liu SM
J Cancer Res Clin Oncol; 2023 Oct; 149(13):12249-12263. PubMed ID: 37434092
[TBL] [Abstract][Full Text] [Related]
8. A cuproptosis random forest cox score model-based evaluation of prognosis, mutation characterization, immune infiltration, and drug sensitivity in hepatocellular carcinoma.
Liu R; Liu Y; Zhang F; Wei J; Wu L
Front Immunol; 2023; 14():1146411. PubMed ID: 37063920
[TBL] [Abstract][Full Text] [Related]
9. Cuproptosis-related molecular patterns and gene (ATP7A) in hepatocellular carcinoma and their relationships with tumor immune microenvironment and clinical features.
Li S; Weng J; Xiao C; Lu J; Cao W; Song F; He Z; Zhang P; Zhu Z; Xu J
Cancer Rep (Hoboken); 2023 Dec; 6(12):e1904. PubMed ID: 37885090
[TBL] [Abstract][Full Text] [Related]
10. Cuproptosis regulator-mediated patterns associated with immune infiltration features and construction of cuproptosis-related signatures to guide immunotherapy.
Wang G; Xiao R; Zhao S; Sun L; Guo J; Li W; Zhang Y; Bian X; Qiu W; Wang S
Front Immunol; 2022; 13():945516. PubMed ID: 36248857
[TBL] [Abstract][Full Text] [Related]
11. Identification of cuproptosis-related subtypes, cuproptosis-related gene prognostic index in hepatocellular carcinoma.
Ding L; Li W; Tu J; Cao Z; Li J; Cao H; Liang J; Liang Y; Yu Q; Li G
Front Immunol; 2022; 13():989156. PubMed ID: 36177029
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of a stemness-based classifier for prognosis and immunotherapy response of hepatocellular carcinoma based on bioinformatics and machine-learning strategies.
Chen E; Zou Z; Wang R; Liu J; Peng Z; Gan Z; Lin Z; Liu J
Front Immunol; 2024; 15():1244392. PubMed ID: 38694506
[TBL] [Abstract][Full Text] [Related]
13. Construction and systematic evaluation of a machine learning-based cuproptosis-related lncRNA score signature to predict the response to immunotherapy in hepatocellular carcinoma.
Lu D; Liao J; Cheng H; Ma Q; Wu F; Xie F; He Y
Front Immunol; 2023; 14():1097075. PubMed ID: 36761763
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive analysis of cuproptosis-related prognostic gene signature and tumor immune microenvironment in HCC.
Qin H; Sheng W; Zhang G; Yang Q; Yao S; Yue Y; Zhang P; Zhu Y; Wang Q; Chen Y; Zeng H; Weng J; Yu F; Yang J
Front Genet; 2023; 14():1094793. PubMed ID: 36891150
[No Abstract] [Full Text] [Related]
15. Novel Molecular Subtyping Scheme Based on In Silico Analysis of Cuproptosis Regulator Gene Patterns Optimizes Survival Prediction and Treatment of Hepatocellular Carcinoma.
Jiang H; Chen H; Wang Y; Qian Y
J Clin Med; 2023 Sep; 12(18):. PubMed ID: 37762710
[TBL] [Abstract][Full Text] [Related]
16. Development and experimental verification of a prognosis model for cuproptosis-related subtypes in HCC.
Wang Y; Zhang Y; Wang L; Zhang N; Xu W; Zhou J; Zhao Y; Zhu W; Zhang T; Wang L
Hepatol Int; 2022 Dec; 16(6):1435-1447. PubMed ID: 36065073
[TBL] [Abstract][Full Text] [Related]
17. DLAT as a Cuproptosis Promoter and a Molecular Target of Elesclomol in Hepatocellular Carcinoma.
Gao F; Yuan Y; Ding Y; Li PY; Chang Y; He XX
Curr Med Sci; 2023 Jun; 43(3):526-538. PubMed ID: 37286711
[TBL] [Abstract][Full Text] [Related]
18. System analysis based on the cuproptosis-related genes identifies LIPT1 as a novel therapy target for liver hepatocellular carcinoma.
Yan C; Niu Y; Ma L; Tian L; Ma J
J Transl Med; 2022 Oct; 20(1):452. PubMed ID: 36195876
[TBL] [Abstract][Full Text] [Related]
19. Cuproptosis-related prognostic signatures predict the prognosis and immunotherapy in HCC patients.
Peng H; Zou Z; Xiang Z; Lu X; Zhang Y; Peng X
Medicine (Baltimore); 2023 Aug; 102(34):e34741. PubMed ID: 37653738
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive analysis of cuproptosis-related lncRNAs in immune infiltration and prognosis in hepatocellular carcinoma.
Liu C; Wu S; Lai L; Liu J; Guo Z; Ye Z; Chen X
BMC Bioinformatics; 2023 Jan; 24(1):4. PubMed ID: 36597032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
